First clinical experience with a new injectable recombinant human collagen scaffold combined with autologous platelet-rich plasma for the treatment of lateral epicondylar tendinopathy (tennis elbow)

Farkash, Uri; Avisar, Erez; Volk, Ido; Slevin, Omer; Shohat, Noam; Haj, Madi El; Dolev, Eran; Ashraf, Eran; Luria, Shai

doi:10.1016/j.jse.2018.09.007

Cited by 21 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, rhCOL type I has been combined with platelet-rich plasma to create a flowable wound-healing gel [84]. Upon injection into a wound site, the gel forms a collagen-fibrin matrix capable of triggering cellular recruitment, adhesion and proliferation [85]. The addition of platelet-rich plasma results in platelet-derived growth factor and vascular endothelial growth factor production within the matrix, further enhancing the proliferation of fibroblasts and vascular recruitment [84,85,86].…”

Section: Sources Of Collagenmentioning

confidence: 99%

“…Upon injection into a wound site, the gel forms a collagen-fibrin matrix capable of triggering cellular recruitment, adhesion and proliferation [85]. The addition of platelet-rich plasma results in platelet-derived growth factor and vascular endothelial growth factor production within the matrix, further enhancing the proliferation of fibroblasts and vascular recruitment [84,85,86]. In vivo research indicates that wounds treated with rhCOL type I synthesized by a tobacco recombinant system significantly accelerate wound closure, when compared to animal-derived collagen flowable gels [84].…”

Section: Sources Of Collagenmentioning

confidence: 99%

See 1 more Smart Citation

Sources of Collagen for Biomaterials in Skin Wound Healing

2019

View full text Add to dashboard Cite

Collagen is the most frequently used protein in the fields of biomaterials and regenerative medicine. Within the skin, collagen type I and III are the most abundant, while collagen type VII is associated with pathologies of the dermal–epidermal junction. The focus of this review is mainly collagens I and III, with a brief overview of collagen VII. Currently, the majority of collagen is extracted from animal sources; however, animal-derived collagen has a number of shortcomings, including immunogenicity, batch-to-batch variation, and pathogenic contamination. Recombinant collagen is a potential solution to the aforementioned issues, although production of correctly post-translationally modified recombinant human collagen has not yet been performed at industrial scale. This review provides an overview of current collagen sources, associated shortcomings, and potential resolutions. Recombinant expression systems are discussed, as well as the issues associated with each method of expression.

show abstract

Section: Sources Of Collagenmentioning

confidence: 99%

Section: Sources Of Collagenmentioning

confidence: 99%

Sources of Collagen for Biomaterials in Skin Wound Healing

2019

View full text Add to dashboard Cite

show abstract

“…Collplant is the commercial product developed from this synthesis process and has undergone clinical trials for wound healing and tissue repair. [ 99,100 ]…”

Section: Source Of Collagenmentioning

confidence: 99%

Bioprinting of Collagen: Considerations, Potentials, and Applications

Lee

Suen

Ng³

et al. 2020

Macromolecular Bioscience

View full text Add to dashboard Cite

Collagen is the most abundant extracellular matrix protein that is widely used in tissue engineering (TE). There is little research done on printing pure collagen. To understand the bottlenecks in printing pure collagen, it is imperative to understand collagen from a bottom‐up approach. Here it is aimed to provide a comprehensive overview of collagen printing, where collagen assembly in vivo and the various sources of collagen available for TE application are first understood. Next, the current printing technologies and strategy for printing collagen‐based materials are highlighted. Considerations and key challenges faced in collagen printing are identified. Finally, the key research areas that would enhance the functionality of printed collagen are presented.

show abstract

“…For instance, FibroGen, Inc. (San Francisco, CA, USA) manufactures recombinant collagens in yeast cells, while CollPlant Ltd. (Rehovot, Israel) employs tobacco plants as collagen-producing factories. According to published literature, these companies mainly focus on collagen I and collagen III for manufacturing biomedical products, including artificial corneas, injectable constructs, and wound-dressing materials [74][75][76]. They use proteolytic enzymes to extract collagens from the hosts' crude materials [77].…”

Section: Collagen Expression Systemsmentioning

confidence: 99%

Three Decades of Research on Recombinant Collagens: Reinventing the Wheel or Developing New Biomedical Products?

Fertala

2020

Bioengineering

View full text Add to dashboard Cite

Collagens provide the building blocks for diverse tissues and organs. Furthermore, these proteins act as signaling molecules that control cell behavior during organ development, growth, and repair. Their long half-life, mechanical strength, ability to assemble into fibrils and networks, biocompatibility, and abundance from readily available discarded animal tissues make collagens an attractive material in biomedicine, drug and food industries, and cosmetic products. About three decades ago, pioneering experiments led to recombinant human collagens’ expression, thereby initiating studies on the potential use of these proteins as substitutes for the animal-derived collagens. Since then, scientists have utilized various systems to produce native-like recombinant collagens and their fragments. They also tested these collagens as materials to repair tissues, deliver drugs, and serve as therapeutics. Although many tests demonstrated that recombinant collagens perform as well as their native counterparts, the recombinant collagen technology has not yet been adopted by the biomedical, pharmaceutical, or food industry. This paper highlights recent technologies to produce and utilize recombinant collagens, and it contemplates their prospects and limitations.

show abstract

First clinical experience with a new injectable recombinant human collagen scaffold combined with autologous platelet-rich plasma for the treatment of lateral epicondylar tendinopathy (tennis elbow)

Cited by 21 publications

References 39 publications

Sources of Collagen for Biomaterials in Skin Wound Healing

Sources of Collagen for Biomaterials in Skin Wound Healing

Bioprinting of Collagen: Considerations, Potentials, and Applications

Three Decades of Research on Recombinant Collagens: Reinventing the Wheel or Developing New Biomedical Products?

Contact Info

Product

Resources

About